Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29
Epistemonikos ID: ad63649dea5c46458ef8cb4a54dd5471fc3f8ced
First added on: Oct 06, 2020